Clinical Trial News and Research

RSS

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Lexicon Pharmaceuticals, Inc.'s telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine Tumor Society Annual Symposium in Austin, Texas.

19 Oct 2015

LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, announced today that Enstilar has been approved by the U.S. Food and Drug Administration for the topical treatment of plaque psoriasis in adults 18 years of age and older.

19 Oct 2015

Allergan completes acquisition of AqueSys

Allergan plc, a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of AqueSys, Inc. a clinical-stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma.

19 Oct 2015

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced that yesterday it presented positive preclinical data demonstrating the promising potential of its lead product candidate VAL-083 (dianhydrogalactitol) as a treatment for ovarian cancer.

19 Oct 2015

Pulsar Vascular reaches target enrollment in PulseRider clinical trial for treatment of intracranial aneurysms

Pulsar Vascular, an innovative medical device company, focused on breakthrough technology in the neurovascular space, announced today that they have reached the target enrollment in their clinical trial for PulseRider, the company's lead product.

19 Oct 2015

University of Maryland develops GammaPod system to treat early-stage breast cancer

After more than a decade of research and development, researchers in the Department of Radiation Oncology at the University of Maryland School of Medicine will begin enrolling patients in the first clinical trial of GammaPod, a new high-precision, image-guided radiation therapy system specifically designed to treat early-stage breast cancer.

19 Oct 2015

Doctors use MR-guided focused ultrasound to treat essential tremor

The Ohio State University Wexner Medical Center is one of six locations nationally - and the only one in the Midwest - studying the safety and effectiveness of a promising new technology using MR-guided focused ultrasound to treat patients suffering from essential tremor as part of a multi-center FDA trial.

18 Oct 2015

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.

16 Oct 2015

UM SOM researchers to initiate first clinical trial of GammaPod system in patients with early-stage breast cancer

16 Oct 2015

Two-Level IDE approval granted to Simplify Medical’s cervical artificial disc

Simplify Medical, Inc. is pioneering disc arthroplasty with the non-metal, MRI compatible Simplify™ Disc, a cervical artificial disc.

16 Oct 2015

New approaches to treating amblyopia

Amblyopia, commonly known as "lazy-eye," has been classically treated by patching the strong eye to force the weaker eye to be used. However, the concept of binocular dysfunction, in which the brain suppresses the image from the weaker eye in favor of the stronger eye, has motivated new approaches to amblyopia treatment.

15 Oct 2015

Gene therapy preserves vision in canine model of late-stage retinitis pigmentosa

Gene therapy preserved vision in a study involving dogs with naturally occurring, late-stage retinitis pigmentosa, according to research funded by the National Eye Institute (NEI), part of the National Institutes of Health. The findings contribute to the groundwork needed to move gene therapy forward into clinical trials for people with the blinding eye disorder, for which there is currently no cure.

15 Oct 2015

Specific gene signature could help predict survival outcomes among children with intermediate-risk RMS

Among children with intermediate-risk rhabdomyosarcoma (RMS) that is negative for a fusion gene, those who had a high score of a specific gene signature called MG5 had poorer survival outcomes compared with those who had a low score of MG5.

15 Oct 2015

New $6.7 million project aims to help kidney dialysis patients live longer

Helping kidney dialysis patients have healthier treatment sessions and longer lives is the goal of a new $6.7 million project at the University of Michigan.

15 Oct 2015

LEADERS FREE clinical trial demonstrates superior safety, efficacy for BioFreedom compared with bare-metal stent

Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, announced today that the LEADERS FREE clinical trial demonstrated superior safety and efficacy for BioFreedom compared with a bare-metal stent (BMS).

15 Oct 2015

CU Cancer Center study reports 'robust antitumor activity' of TAK-733 drug in mouse models of colorectal cancer

A University of Colorado Cancer Center study recently published online ahead of print in the journal Oncotarget reports "robust antitumor activity" of the drug TAK-733 in cells and mouse models of colorectal cancer.

14 Oct 2015

Insulin dose not independent risk factor for cardiovascular death

A NIH-sponsored double-blinded, randomized clinical trial entitled Action to Control Cardiovascular Risk in Diabetes (ACCORD study) came to a halt seven years ago after patients receiving more intensive diabetes therapy were found to have a higher mortality rate, compared to the standard therapy.

14 Oct 2015

Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

Preclinical experiments led by a team of researchers at VCU Massey Cancer Center have shown that blocking the production of a protein known as chromodomain helicase DNA-binding protein 4 (CHD4) may help increase the effectiveness of first-line treatments for acute myeloid leukemia (AML), a particularly lethal blood cancer that is increasing in incidence among older adults.

14 Oct 2015

XTL signs agreement with Yeda to amend development milestones for lupus treatment

XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, today announced that it has reached agreement with Yeda Research and Development Company Ltd. to amend the development milestones in the License Agreement signed between the parties in January 2014 for the development of hCDR1 for the treatment of systemic lupus erythematosus (SLE).

13 Oct 2015

Penn researchers show that canine X-linked retinitis pigmentosa can be cured over the long term

Three years ago, a team from the University of Pennsylvania announced that they had cured X-linked retinitis pigmentosa, a blinding retinal disease, in dogs. Now they've shown that they can cure the canine disease over the long term, even when the treatment is given after half or more of the affected photoreceptor cells have been destroyed.

13 Oct 2015

Clinical Trial News and Research

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

Allergan completes acquisition of AqueSys

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

Pulsar Vascular reaches target enrollment in PulseRider clinical trial for treatment of intracranial aneurysms

University of Maryland develops GammaPod system to treat early-stage breast cancer

Doctors use MR-guided focused ultrasound to treat essential tremor

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

UM SOM researchers to initiate first clinical trial of GammaPod system in patients with early-stage breast cancer

Two-Level IDE approval granted to Simplify Medical’s cervical artificial disc

New approaches to treating amblyopia

Gene therapy preserves vision in canine model of late-stage retinitis pigmentosa

Specific gene signature could help predict survival outcomes among children with intermediate-risk RMS

New $6.7 million project aims to help kidney dialysis patients live longer

LEADERS FREE clinical trial demonstrates superior safety, efficacy for BioFreedom compared with bare-metal stent

CU Cancer Center study reports 'robust antitumor activity' of TAK-733 drug in mouse models of colorectal cancer

Insulin dose not independent risk factor for cardiovascular death

Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

XTL signs agreement with Yeda to amend development milestones for lupus treatment

Penn researchers show that canine X-linked retinitis pigmentosa can be cured over the long term

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer